Alcidion posts record H1 FY26 as recurring revenue and flagship contracts drive growth

The latest announcement is out from Alcidion Group Limited ( (AU:ALC) ).

Alcidion reported its strongest half-year performance for H1 FY26, with revenue rising 44% to $25.5 million and underlying EBITDA jumping 675% to $4.2 million, supported by balanced contributions from the UK and ANZ markets. Annual recurring revenue reached $31.1 million, aided by major deployment projects and an expanding customer base, including the Australian Defence Force via Leidos Australia.

The company’s contracted FY26 revenue stood at $43.1 million as of 31 December, up 40% year on year and excluding expected revenue from a pending Electronic Patient Record deal with University Hospitals Sussex NHS Foundation Trust, estimated at a total contract value of at least $35 million. Management reaffirmed guidance for FY26 revenue to exceed $50 million and EBITDA above $5 million, highlighting strong operating leverage, continued positive operating cash flow and a solid balance sheet with $14.2 million in cash and no debt.

The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.11 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.

More about Alcidion Group Limited

Alcidion Group Limited is an Australian health technology company that provides clinical decision support, patient flow management and electronic patient record solutions. Its flagship Miya Precision platform underpins data integration, analytics and workflow tools for acute healthcare providers across Australia, New Zealand and the UK, with a growing focus on large enterprise and defence healthcare deployments.

Average Trading Volume: 1,941,494

Technical Sentiment Signal: Buy

Current Market Cap: A$134.3M

For a thorough assessment of ALC stock, go to TipRanks’ Stock Analysis page.